Natan Yehudit, Blum Yigal Dov, Arav Amir, Poliansky Ylena, Neuman Sara, Ecker Cohen Orit, Ben Yossi
Amorphical Ltd., 11 HaHarash st., Nes-Ziona 7403118, Israel.
A.A. Cash Technology Ltd., 59 Shlomzion Hamalka st., Tel-Aviv 6226618, Israel.
Cancers (Basel). 2023 Jul 26;15(15):3785. doi: 10.3390/cancers15153785.
Amorphous calcium carbonate (ACC) is a non-crystalline form of calcium carbonate, and it is composed of aggregated nano-size primary particles. Here, we evaluated its anti-cancer effect postulated relative to its buffering capabilities in lung cancer.
Tumors were evaluated in vivo using the Lewis lung carcinoma (LLC) mouse cell line and A549 human lung cancer carcinoma cell line. LLC and A549 cells were injected subcutaneously into the right hind leg of mice. Treatments (ACC, cisplatin, vehicle, and ACC with cisplatin, all given via daily IP injections) started once tumors reached a measurable size. Treatments were carried out for 14 days in the LLC model and for 22 and 24 days in the xenograft model (two experiments). LLC tumors were resected from ACC at the end of the study, and vehicle groups were evaluated for cathepsin B activity. Differential gene expression was carried out on A549 cells following 8 weeks of in vitro culture in the presence or absence of ACC in a culture medium.
The ACC treatment decelerated tumor growth rates in both models. When tumor volumes were compared on the last day of each study, the ACC-treated animal tumor volume was reduced by 44.83% compared to vehicle-treated animals in the LLC model. In the xenograft model, the tumor volume was reduced by 51.6% in ACC-treated animals compared to vehicle-treated animals. A more substantial reduction of 74.75% occurred in the combined treatment of ACC and cisplatin compared to the vehicle (carried out only in the LLC model). Cathepsin B activity was significantly reduced in ACC-treated LLC tumors compared to control tumors. Differential gene expression results showed a shift towards anti-tumorigenic pathways in the ACC-treated A549 cells.
This study supports the ACC anti-malignant buffering hypothesis by demonstrating decelerated tumor growth, reduced cathepsin B activity, and altered gene expressions to produce anti-cancerous effects.
无定形碳酸钙(ACC)是碳酸钙的一种非晶态形式,由聚集的纳米级初级颗粒组成。在此,我们评估了其相对于肺癌缓冲能力的抗癌效果。
使用Lewis肺癌(LLC)小鼠细胞系和A549人肺癌细胞系在体内评估肿瘤。将LLC和A549细胞皮下注射到小鼠右后腿。一旦肿瘤达到可测量大小,开始治疗(ACC、顺铂、赋形剂以及ACC与顺铂联合使用,均通过每日腹腔注射给药)。在LLC模型中治疗14天,在异种移植模型中治疗22天和24天(两个实验)。研究结束时从接受ACC治疗的小鼠身上切除LLC肿瘤,并评估赋形剂组的组织蛋白酶B活性。在含有或不含有ACC的培养基中对A549细胞进行8周体外培养后进行差异基因表达分析。
ACC治疗在两个模型中均减缓了肿瘤生长速度。在每项研究的最后一天比较肿瘤体积时,与赋形剂治疗的动物相比,接受ACC治疗的动物肿瘤体积在LLC模型中减少了44.83%。在异种移植模型中,与赋形剂治疗的动物相比,接受ACC治疗的动物肿瘤体积减少了51.6%。与赋形剂相比(仅在LLC模型中进行),ACC和顺铂联合治疗使肿瘤体积减少了74.75%,降幅更大。与对照肿瘤相比,接受ACC治疗的LLC肿瘤中组织蛋白酶B活性显著降低。差异基因表达结果显示,接受ACC治疗的A549细胞向抗肿瘤途径转变。
本研究通过证明肿瘤生长减缓、组织蛋白酶B活性降低以及基因表达改变以产生抗癌作用,支持了ACC抗恶性缓冲假说。